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Pancreatic cancer is a highly aggressive and deadly disease harboring a distinct population of cancer stem cells (CSC)
that is not affected by conventional therapies. A new therapeutic approach using the EpCAM/CD3-bispecific antibody
MT110 is capable of activating and redirecting cytotoxic T cells to eliminate primary human pancreatic cancer stem cells,
which resulted in long-term survival of preclinical xenografts models.
Pancreatic ductal adenocarcinoma (PDAC),
the most frequent form of pancreatic
cancer, is the deadliest solid cancer and
currently the fourth most frequent cause
of cancer-related deaths.
1 PDAC is char-
acterized by late diagnosis due to lack of
early symptoms, extensive metastasis, and
high resistance to chemotherapy and radia-
tion. Despite expanding research activities
in the field of pancreatic tumor and
vascular biology, there has been little
therapeutic progress regarding clinical
endpoints over the past decades. Since
the 1990s, the anti-metabolite gemcita-
bine emerged as the gold standard for
treating patients with PDAC but with a
5-y survival rate of 1–4% and a median
survival period of 4–6 mo, the prognosis
of patients with advanced PDAC remains
extremely poor.
2
Since the establishment of the cancer
stem cell (CSC) hypothesis for leukemia in
1994,
3 convincing evidence has also
emerged for solid tumors that, like adult
tissues, are sustained and promoted by
cells that exhibit features of stem cells such
as unlimited self-renewal capacity. We and
others have recently provided conclusive
evidence for a hierarchical organization of
human PDAC and, even more impor-
tantly, demonstrated that pancreatic CSC
at the top of the hierarchy are driving
metastasis and are resistant to chemother-
apy.
4 If sufficient amounts of gemcitabine
are delivered to the cancer cells in vivo,
which can be achieved by concomitant
administration of stroma-targeting agents
such as inhibitors of the hedgehog path-
way, the bulk of the tumor cells can
indeed be successfully erased as evidenced
by tumor shrinkage. However, as this
initial success is only followed by relapse,
a plausible explanation is that surviving
CSCs are the source of treatment resist-
ance and should at least in part account for
the dismissal prognosis of these patients.
Initial studies from our groups are now
providing increasing evidence that direct
targeting of pancreas CSCs in combina-
tion with elimination of the more differ-
entiated tumor cells bears therapeutic
value as this significantly prolonged sur-
vival in preclinical xenograft models.
5,6
While these studies were based on the
inhibition of key regulatory pathways that
are crucially relevant for the self-renew
capacity of CSC, more recently, we have
also asked about the capability of immune-
based therapy to target pancreatic CSC.
Immune-based therapies could bear the
putative advantage of targeting CSC
irrespective of potentially very diverse
genetic and epigenetic alterations.
Immuno-based treatment strategies are a
newly emerging therapeutic modality for
PDAC, where immune effector mech-
anism can be induced and directed toward
antigens preferentially expressed by tumor
cells including CSC.
Several antigens have been identified
in the past years to target tumor cells. A
recent study by Visus and colleagues took
advantage of the ALDH activity as a
marker to identify and selectively target
the CSC population using several cell lines
including pancreatic cancer cells.
7 The
authors generated in vitro ALDH1A1-
specific CD8
+ T cells in order to eliminate
ALDH
bright CSC in preclinical models of
human tumor xenografts and observed
growth inhibition and reduced metastasis.
However, a major concern for this appro-
ach represents the fact that ALDH1A1-
specific CD8
+ T cells will most likely also
target normal ALDH
bright stem cells, which
can for example be found in the hemato-
poietic system.
In our recent work,
8 we evaluated the
therapeutic value of the bispecific anti-
body MT110 targeting the T-cell receptor
CD3 complex and Epithelial cell adhesion
molecule (EpCAM; CD326). EpCAM is
frequently overexpressed and functionally
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altered in epithelial cancer cells, including
CSC,
9 and therefore is becoming accessible
on the surface of these cells. In contrast, in
normal epithelial cells and embryonic stem
cells, EpCAM is sequestered within inter-
cellular boundaries. Therefore, EpCAM
represents a promising target for immuno-
therapy of EpCAM-expressing cancer cells
including tumorigenic CSCs.
We first evaluated the effect of MT110
using a dose escalation and time depend-
ent approach in three different primary
PDAC cells isolated from human cancer
tissue samples. We observed that T cells
reach maximal activity for inducing apop-
tosis of cancer cells at a concentration of
100 ng/ml MT110, as demonstrated by
flow cytometry analysis for early T-cell
activation marker CD69 and late activa-
tion marker CD25. Subsequent flow
cytometry analysis for CSC markers iden-
tified by expression of CD133 and SSEA1,
respectively, showed a significant reduc-
tion in the CSC population implying that
they are not spared from the cytotoxic
activity of activated T cells. Moreover, as a
surrogate assay for the self-renewal capa-
city of CSCs, we examined the sphere
formation capacity of the cells following
treatment with MT110. As predicted,
primary cancer cells exposed to MT110
for 7 d showed a significant decline in
sphere formation.
The most defining feature of CSC is
their ability to exclusively form tumors in
vivo. Indeed, CSC treated for 7 d with
MT110 and then implanted into mice
had completely lost their in vivo tumor-
igenicity. Finally and most importantly,
we then studied the treatment effects
of MT110 in vivo using a model of
established primary human PDAC co-
implanted with healthy donor-derived
PBMC. After administration of MT110
we observed a complete stall in tumor
growth over the entire follow-up period
indicating that the tumors were depleted
for tumorigenic/tumor-promoting CSC.
This was also confirmed by flow cytometry
analysis of harvested tumors, which
revealed a depletion for cells expressing
CD133, SSEA-1, and CXCR4 as well
as significantly reduced sphere-formation
capacity in the MT110 group as compared
with tumors harvested from mice treated
with control BiTE.
Apparently, the efficacy of this treat-
ment approach is dependent on the level
of EpCAM expression. In our model
system, we compared 185 cells, which
were derived from a primary PDAC, and
A6L cells, which were derived from a liver
metastasis. Flow cytometry revealed that
185 cells were all EpCAM positive, while
A6L cells also harbored an EpCAM-
negative subpopulation, which could be
further enriched during sphere formation.
Spheres derived from EpCAM-negative
cells are invasive CSC that probably
underwent epithelial-to-mesenchymal
transition (EMT).
10 The presence of this
EpCAM negative subpopulation may
provide an explanation for our observation
that A6L was less responsive to MT110
treatment.
MT110 is currently tested in a dose-
escalating Phase I clinical trial enrolling
patients with diverse epithelial cancers
(lung, colon, gastric). Low toxicity and
early signs of biological activity have
been observed at clinically well-tolerated
doses of MT110 in this first-in-human
clinical trial. Our results derived from
preclinical PDAC models now suggest
that this treatment regimen could also
represent a new opportunity for patients
with PDAC. It is important to note,
however, that the strong fibroblastic
nature of PDAC results in poor tumor
vascularization and may therefore require
simultaneous targeting of the stroma,
e.g., by the addition of hedgehog path-
way inhibitors for sufficient delivery of
MT110 to the cancer cells including the
CSC subpopulation.
6
Figure1. Activation of T cells by MT110 against cancer cells and cancer stem cells.
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